Recent News

• 05.28.2025 - Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
• 05.20.2025 - Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
• 05.13.2025 - Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
• 05.06.2025 - Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
• 05.06.2025 - Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
• 04.21.2025 - Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
• 04.21.2025 - Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
• 03.11.2025 - Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
• 03.11.2025 - Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Recent Filings

• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.09.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEF 14A Other definitive proxy statements
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 8-K Current report